BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26911351)

  • 21. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
    An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
    Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia.
    Tokuda K; Eguchi-Ishimae M; Iwabuki H; Kawakami S; Tauchi H; Ishii E; Eguchi M
    Eur J Haematol; 2015 Feb; 94(2):177-81. PubMed ID: 24766281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
    Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
    Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.
    Bunda S; Qin K; Kommaraju K; Heir P; Ohh M
    Oncogene; 2015 Feb; 34(6):789-97. PubMed ID: 24469048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy.
    Kato M; Yasui N; Seki M; Kishimoto H; Sato-Otsubo A; Hasegawa D; Kiyokawa N; Hanada R; Ogawa S; Manabe A; Takita J; Koh K
    J Pediatr; 2013 Jun; 162(6):1285-8, 1288.e1. PubMed ID: 23403250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and treatment of juvenile myelomonocytic leukemia.
    Sakashita K; Matsuda K; Koike K
    Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations.
    Matsuda K; Taira C; Sakashita K; Saito S; Tanaka-Yanagisawa M; Yanagisawa R; Nakazawa Y; Shiohara M; Fukushima K; Oda M; Honda T; Nakahata T; Koike K
    Blood; 2010 Jul; 115(26):5429-31. PubMed ID: 20595524
    [No Abstract]   [Full Text] [Related]  

  • 29. Myelodysplastic and myeloproliferative disorders of childhood.
    Hasle H
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):598-604. PubMed ID: 27913534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
    Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
    Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.
    Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H
    Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
    Pauli S; Steinemann D; Dittmann K; Wienands J; Shoukier M; Möschner M; Burfeind P; Manukjan G; Göhring G; Escherich G
    Am J Med Genet A; 2012 Mar; 158A(3):652-8. PubMed ID: 22315187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants.
    Baccelli F; Leardini D; Muratore E; Messelodi D; Bertuccio SN; Chiriaco M; Cancrini C; Conti F; Castagnetti F; Pedace L; Pession A; Yoshimi A; Niemeyer C; Tartaglia M; Locatelli F; Masetti R
    Hum Genomics; 2022 Sep; 16(1):40. PubMed ID: 36123612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing.
    Wang WH; Lu MY; Tsai CH; Wang SC; Chou SW; Jou ST
    J Formos Med Assoc; 2021 Apr; 120(4):1148-1152. PubMed ID: 32933826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of splenomegaly in CBL syndrome.
    Coe RR; McKinnon ML; Tarailo-Graovac M; Ross CJ; Wasserman WW; Friedman JM; Rogers PC; van Karnebeek CDM
    Eur J Med Genet; 2017 Jul; 60(7):374-379. PubMed ID: 28414188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
    J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Juvenile myelomonocytic leukaemia and Noonan syndrome.
    Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
    J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and molecular features of
    Yoshida T; Muramatsu H; Wakamatsu M; Sajiki D; Murakami N; Kitazawa H; Okamoto Y; Taniguchi R; Kataoka S; Narita A; Hama A; Okuno Y; Takahashi Y
    Haematologica; 2023 Nov; 108(11):3115-3119. PubMed ID: 37226702
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
    Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.